Glioblastoma multiforme natural history
Glioblastoma multiforme Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Glioblastoma multiforme natural history On the Web |
American Roentgen Ray Society Images of Glioblastoma multiforme natural history |
Risk calculators and risk factors for Glioblastoma multiforme natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
If left untreated, glioblastoma multiforme may extend into the meninges, ventricular wall, or spinal cord. Common complications of glioblastoma multiforme include herniation, hydrocephalus, systemic illness, brainstem invasion by tumor, neutron-induced cerebral injury, weakness, fatigue, numbness, surgical complications, and coma.[1] Prognosis is generally poor, and the 5-year survival rate of patients with glioblastoma multiforme is less than 10%.
Natural History
Complications
Common complications of glioblastoma multiforme include:[1]
- Herniation (axial, transtentorial, subfalcine, tonsillar)
- Hydrocephalus
- Systemic illness
- Brainstem invasion by tumor
- Neutron-induced cerebral injury
- Weakness
- Fatigue
- Numbness
- Surgical complications (cerebral hemorrhage, edema)
- Coma
Prognosis
- Prognosis is generally poor, and the 5-year survival rate of patients with glioblastoma multiforme is less than 10%.
- Negative prognostic factors include:[2]
- With standard treatment (surgery, radiotherapy, and chemotherapy), the median survival is approximately 14 months.[3]
- Removal of 98% or more of the tumor by surgery has been associated with a better prognosis.
References
- ↑ 1.0 1.1 Silbergeld DL, Rostomily RC, Alvord EC (1991). "The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults". J Neurooncol. 10 (2): 179–85. PMID 1654403.
- ↑ Prognosis of glioblastoma multiforme. Dr Dylan Kurda and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/glioblastoma
- ↑ Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann J, Janzer R, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross J, Eisenhauer E, Mirimanoff R (2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". N Engl J Med. 352 (10): 987–96. PMID 15758009.